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One Sentence Summary: Integrated longitudinal genomic and epidemiological surveillance of 
methicillin-resistant Staphylococcus aureus (MRSA) in the East of England revealed extensive 
transmission in hospitals and the community, and provide evidence for the need to review 
infection control policy and practice.  
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Abstract: Snapshots of MRSA transmission have been provided by genome sequencing in the 
context of suspected outbreaks and isolated hospital wards. Scale-up to populations is now 
required to establish the full potential of this technology for surveillance. We prospectively 
identified all individuals over 12 months who had at least one MRSA positive sample processed 
by a routine diagnostic microbiology laboratory in the East of England, which received samples 
from three hospitals and 75 general practitioner (GP) practices. We sequenced at least one 
MRSA isolate from 1,465 individuals (2,282 MRSA isolates) and recorded epidemiological data. 
An integrated epidemiological and phylogenetic analysis revealed 173 transmission clusters 
containing between 2 and 44 cases and involving 598 people (40.8%). Of these, 118 clusters 
(371 people) involved hospital contacts alone, 27 clusters (72 people) involved community 
contacts alone, and 28 clusters (157 people) had both types of contact. Community- and hospital-
associated MRSA lineages were equally capable of transmitting in the community, with 
instances of spread in households, long-term care facilities (LTCF) and GP practices. This 
provides a comprehensive picture of MRSA transmission in an entire sampled population, and 
evidence to guide a review of infection control policy and practice.  
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Introduction 
Staphylococcus aureus is responsible for a high proportion of community-associated invasive 
and soft-tissue infections, and is a leading cause of healthcare-associated infections (1). This 
burden is compounded by MRSA infection, which results in increased mortality and 
hospitalization costs and longer hospital stays compared to methicillin-susceptible S. aureus 
infections (2). Successful reduction of MRSA infection rates depends on preventing MRSA 
transmission and detecting and containing outbreaks (3). Understanding the settings and 
circumstances under which MRSA evades current infection control measures is central to 
designing new strategies to reduce transmission. 
 
MRSA carriage and infection has historically been associated with healthcare settings. Recent 
studies have demonstrated the value of applying whole-genome sequencing (WGS) to define the 
spread of MRSA (4–10) and a range of other pathogens in hospitals. WGS provides the ultimate 
resolution to discriminate between bacterial isolates, and when combined with epidemiological 
data enables the reconstruction of transmission networks. Previous studies have largely focused 
on suspected outbreaks (4–6), or transmission in high-risk settings such as intensive care units 
(7–10). These snapshots have confirmed the potential of WGS to confirm or refute outbreaks, but 
the value that could be derived from applying this to entire populations, including those that 
bridge the divide between hospitals and the community, is unknown.  Here, we report the 
findings of a 12-month prospective study of all MRSA-positive individuals detected by a large 
diagnostic microbiology laboratory in England in which an integrated analysis of 
epidemiological and sequence data provided a holistic picture of MRSA transmission.  
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Results  
Study participants and isolates 
We identified 1,465 MRSA-positive individuals in the East of England over a 12-month period 
by screening all samples submitted to a diagnostic microbiology laboratory by three hospitals 
and 75 GP practices (see Fig. 1 for geographical distribution). Cases had a median age of 68 
years (range newborns to 101 years, interquartile range (IQR) 46 to 82 years). We sequenced 
2,282 isolates cultured from their multisite screens (n=1,619) or diagnostic specimens (n=663), 
which equated to one isolate from 1,006 cases and a median of 2 isolates (range 2-15, IQR 2 to 
3) from 459 cases (see Supplementary Methods for rationale for selecting isolates for sequencing 
and fig. S1 for number of isolates sequenced per case). Around 80% of sequenced MRSA 
isolates were from samples submitted by the three study hospitals (1,453 multisite screens and 
372 diagnostic specimens), with the remainder submitted by GP practices (166 multisite screens 
and 291 diagnostic specimens). Multi-locus sequence types (STs) were derived from sequence 
data, which revealed that the majority of isolates belonged to clonal complex (CC) 22 
(1,667/2,282, 73%), the predominant healthcare-associated lineage in the United Kingdom (UK) 
(11). This was followed in frequency by CC30 (n=129, 5.6%), CC5 (n=108, 4.7%), CC1 (n=105, 
4.6%) and CC8 (n=87, 3.8%) (see table S1 for CC designation of the entire collection). 
Supplementary Methods provides a detailed description of the patient data collected, 
microbiology, sequencing methodology and sequence data analyses, and fig. S2 shows a 
flowchart summarizing the data types used and analyses.  
 
Integration of genomic and epidemiological data 
We initially divided the 2,282 MRSA into clusters containing isolates that were no more that 50 
single-nucleotide polymorphisms (SNPs) different based on core genome comparisons. 
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Supplementary Methods describes the rationale for the cut-off used. This led to the identification 
of 173 separate phylogenetic clusters. MRSA isolated from more than half of cases (785/1465, 
53.6%) were genetically linked to MRSA from at least one other case based on isolates 
belonging to the same cluster. The next step was to apply epidemiological data (hospital 
admission and ward movement data, GP registration and residential postcode) to this clustering 
framework to determine links between cases within each cluster, which ignored the traditional 
categorization of lineages as community- or hospital-associated. Figure S3 provides an overview 
of how the bacterial phylogeny and patient epidemiological data were integrated to define and 
classify transmission clusters. This revealed that 598/785 (76.2%) cases had an identifiable 
MRSA-positive contact with at least one other study case in a hospital setting and/or in the 
community (Table 1). 
 
It is possible for epidemiological links between MRSA-positive individuals to arise by chance 
when MRSA carriers are admitted to hospital wards or other healthcare facilities with a high 
patient turnover and/or a proportionately higher prevalence of MRSA cases than the hospital or 
community averaged baseline. To assess the potential impact of this we determined the strength 
of epidemiological links between people with genetically unrelated isolates (separated by more 
than 50 SNPs). This was achieved by a systematic pairwise comparison of 1040 cases with 
MRSA CC22. A total of 540,280 unique pairwise case comparisons were made, of which 
534,417 had more than 50 SNPs (table S2).  The instances of shared wards, GP practices, and 
postcodes was uncommon (wards/GP practices) or very rare (postcodes) for case-pairs positive 
for unrelated CC22 MRSA (table S2). This analysis led us to classify shared postcodes (present 
in 0.04% of genetically unrelated cases), GP practice and ward contacts (<1% of genetically 
unrelated cases) other than the Accident and Emergency Department (A&E) (6.91%) as strong 
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epidemiological links.  Admission to the same hospital (particularly hospital A) was common in 
unrelated cases and considered a weak epidemiological link. 
 
Each case was paired with the individual whose MRSA isolate was the closest genetic match, 
after which the genetic distance between each MRSA pair was plotted against six different 
categories of epidemiological contact (Fig. 2). This demonstrated a direct relationship between 
bacterial relatedness and strength of epidemiological contact. 
 
Evidence of MRSA transmission in the community 
Twelve per cent of cases (72/598) with both bacterial and epidemiological links could be 
resolved into 27 distinct community transmission clusters. MRSA lineages regarded as 
community-associated (CA-MRSA) - which in the UK include CC1, CC5, CC8, CC45 and CC80 
- were associated with 9 separate community transmission clusters (Table 1). However, most 
community clusters involved hospital-associated lineages (17 separate CC22 clusters involving 
50/72 cases (69%), and one CC30 cluster involving 3/72 cases (4%)). To contextualize the 
MRSA CC22 isolates associated with transmission in the community we constructed a 
phylogenetic tree containing all CC22 study isolates. This showed that CC22 associated with 
community clusters were scattered throughout the phylogenetic tree, interspersed with clusters 
associated with cases with hospital contacts alone (Fig. 3). This indicates that CC22 isolates that 
are transmitted in the community belong to the wider CC22 population, with no evidence for 
specific genetic subsets. We also identified transmission clusters relating to three independent 
GP practices, the largest of which contained 13 cases. All cases with shared postcodes were 
further investigated to determine whether they shared a residential address. This confirmed that 
MRSA transmission had occurred in at least eleven separate households (25 cases) and in eight 
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LTCFs (22 cases) (Table 1). A pictorial representation of exemplars of transmission at a GP 
practice, LTCF and household is shown in fig. S4, A-C.  
 
Evidence of MRSA transmission in hospitals 
More than half of cases with epidemiological and bacterial genomic links (371/598, 62%) 
resided in transmission clusters with hospital contacts, of which 255 cases had ward contacts. 
The 371 cases were resolved into 118 different clusters each involving between 2 and 44 
individuals (Table 1). We narrowed down further investigation to those clusters that contained 
five or more patients (9 clusters, see table S3 for details), and evaluated these for instances of 
direct ward contact (same ward, overlapping admission dates) or indirect ward contact (same 
ward, no overlap in admission dates). Where available, the presence of a negative MRSA culture 
followed by a positive MRSA culture was interpreted as additional evidence of hospital 
acquisition. The specific ward where MRSA had been putatively acquired could be determined 
in 3 of the 9 clusters, one of which is depicted in Fig 4A. This ward-centric pattern occurred in 
two different hospitals and across different clonal complexes (CC22, CC30 and CC15). Of note, 
we observed that there was a time delay between presumptive acquisition date and first clinical 
detection of MRSA-positivity in most cases (6/8, 3/4 and 3/5 patients). For the remaining six 
hospital clusters, multiple wards in the same hospital were plausible places of acquisition. We 
also observed a pattern of transmission that centered around specific individuals, in which the 
movement of a single, persistently MRSA positive index patient through multiple wards resulted 
in MRSA acquisition by numerous others patients. This patient-centric pattern of transmission 
was identified in three transmission clusters (Fig. 4B, Fig S2 E & F) and was observed in two 
different hospitals and for two clonal complexes (CC22 and CC30). Acquisition by other cases 
was associated with a high rate of indirect ward acquisition. 
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MRSA transmission at the hospital-community interface 
We identified 28 clusters (157 cases) that contained a mixture of people with community and 
hospital epidemiological links (Table 1).  Further analysis of 15 clusters that contained five or 
more cases (detailed in table S3) revealed instances of community-onset transmission followed 
by onward nosocomial dissemination, and hospital-onset transmission followed by nosocomial 
and community spread in CC30 and CC22 clusters. A pictorial representation of exemplars of 
these transmission patterns is shown in fig. S4, D-F.   
 
Discussion  
Our findings have important implications for infection control policy and practice. MRSA 
transmission in our study population was not attributable to large nosocomial outbreaks, but 
resulted from the cumulative effect of numerous clinically unrecognized episodes. We detected 
173 separate genetic clusters that mapped to numerous different locations over the course of 12 
months, which is indicative of repeated lapses in infection control. There are several 
explanations for extensive unrecognized transmission, including lack of hospital discharge 
swabbing, and the fact that place of acquisition is often different to the place of detection and 
separated by a period of days, weeks or months. This indicates the need for outbreak 
investigations to widen their scope in time and place when considering potential MRSA contacts. 
 
Standard infection control practice centered on a ward-based approach may also fail to detect the 
impact of longitudinal patient-centric transmission. We identified a critical role for some 
persistent carriers who spread MRSA in multiple wards during complex healthcare pathways. 
This frequently involved indirect transmission, in which apparent acquisition by a new case 
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occurred after the index case had left the ward, which is suggesting of environmental 
contamination or colonized healthcare workers. Further studies are needed to identify host 
factors responsible for persistent carriage associated with a high risk of MRSA transmission, to 
facilitate risk stratification and targeted allocation of isolation facilities where these are a limited 
resource. 
 
It is generally accepted that the majority of MRSA lineages have either become adapted to 
persist and spread in hospitals, or are sufficiently fit to compete with other S. aureus lineages 
associated with community-associated carriage (12). CC22 is the predominant healthcare-
associated lineage MRSA lineage in the UK (~70%) followed in frequency by CC30, and most 
on-going MRSA transmission is assumed to occur in healthcare settings. We expected that most 
clusters caused by CC22 and CC30 MRSA would map to hospitals, but instead found 
considerable CC22 transmission in the community. Furthermore, clusters associated with 
community transmission of MRSA CC22 were distributed across the CC22 phylogeny and were 
interspersed with hospital-related clusters. This provides definitive evidence for the spread of so-
called hospital-associated lineages such as CC22 through transmission networks that include the 
community. The repeated introduction of MRSA from the community into hospitals and vice 
versa signals the need for more robust action to detect and tackle community-associated carriage.   
 
By including patient epidemiological information, we found that residential postcodes and GP 
registration information were strong epidemiological markers of MRSA transmission. Sharing 
the same postcode and/or GP practice by two or more MRSA-positive patients often indicated an 
outbreak, some of which spanned over several months. Our findings support the routine 
collection of postcodes and GP registration as an integral part of routine surveillance to capture 
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putative MRSA outbreaks in the community. This could guide a targeted approach to the use of 
WGS to confirm or refute transmission and direct infection control interventions that curtails 
further dissemination.  
 
We acknowledge several limitations of this study. The study design did not include longitudinal 
or discharge MRSA screening in hospitals, or screening of environmental reservoirs and 
healthcare workers. Furthermore, sampling of the community was opportunistic and relied on 
samples submitted to the diagnostic microbiology. We acknowledge that this would mean failure 
to detect some MRSA carriers involved in our transmission clusters, and that undetected carriers 
results in incomplete transmission routes being reconstructed. Non-sampled carriers explain why 
the MRSA isolate from 680 cases was not linked to the MRSA from any other case, and why 193 
cases whose isolate resided in a genetic cluster had no identifiable epidemiological contact. 
Despite detecting multiple transmission clusters, we are also likely to have underestimated the 
full extent of MRSA transmission attributable to nosocomial and community sources because of 
under-sampling of the entire population served by the diagnostic laboratory at CUH. 
 
In conclusion, we provide evidence for the value of integrated epidemiological and genomic 
surveillance of a population that access the same healthcare referral network in a substantial 
geographic region of England. The large number of patients screened here allowed us to sample 
MRSA lineages that are not dominant in the UK but are endemic in other areas of the world 
including USA300 (prevalent in the United States) (13), the European CA-MRSA CC80 (14), 
and the Taiwanese CC59 clone (prevalent in Asia) (15). The identification of transmission 
clusters involving these lineages in hospitals, the community and at the hospital-community 
interface suggest that our findings are likely to be more widely applicable.  
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Materials and Methods 
Experimental design 
We conducted a 12-month prospective observational cohort study between April 2012 and April 
2013 to identify consecutive individuals with MRSA-positive samples processed by the Clinical 
Microbiology and Public Health Laboratory at the Cambridge University Hospitals NHS 
Foundation Trust (CUH). This facility received samples from three hospitals (referred to as A, B 
and C) and 75 GP practices in the East of England. All hospital in-patients were routinely 
screened for MRSA on admission to hospital, and screening was repeated weekly in critical care 
units. Compliance with mandatory admission screening at the three study hospitals was 85-90% 
(personal communication, Dr. Nicholas Brown, CUH). Additional clinical specimens were taken 
as part of routine clinical care. In the community, there was no formal MRSA screening and 
specimens were taken by GPs or community nursing teams for clinical purposes, meaning that 
coverage was not complete. Epidemiological data (including hospital ward stays and residential 
postcodes) were recorded for all MRSA-positive cases. Detailed methodology is provided in 
Supplementary Methods, and a flowchart summarizing the data types and analyses undertaken is 
shown in fig. S2. The study protocol was approved by the National Research Ethics Service (ref: 
11/EE/0499), the National Information Governance Board Ethics and Confidentiality Committee 
(ref: ECC 8-05(h)/2011), and the Cambridge University Hospitals NHS Foundation Trust 
Research and Development Department (ref: A092428). 
 
DNA sequencing and genomic analyses 
A total of 3,053 MRSA isolates were collected during the study, of which 2,320 were selected 
for WGS. A detailed description of the rationale for selecting isolates for sequencing and 
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genomic methodologies is provided in Supplementary Methods. In brief, DNA was extracted, 
libraries prepared and 100-bp paired end sequences determined for 2,320 isolates on an Illumina 
HiSeq2000, as previously described (11). Of these, 2,282 were further analysed after passing 
quality control (see Supplementary Methods). Genomes were de novo assembled using Velvet 
(16). STs were derived from assemblies and CCs assigned. All isolates assigned to the same CC 
were mapped using SMALT (http://www.sanger.ac.uk/science/tools/smalt-0) to the most closely 
related reference genome. SNPs were identified from BAM files using SAMTOOLS (17). SNPs 
at regions annotated as mobile genetic elements were removed from whole-genome alignments 
and maximum likelihood trees created using RAxML (18) for each CC. Pairwise genetic 
distances between isolates of the same CC were calculated based on the number SNPs in the core 
genome. Sequence data were submitted to the European Nucleotide Archive 
(www.ebi.ac.uk/ena) under the accession numbers listed in Supplementary Data 1.  
 
Epidemiological analysis 
We established epidemiological links between each pair of MRSA-positive individuals (termed 
case-pairs) through a systematic comparison. Hospital contacts were categorized as follows: 
direct ward contact if a case-pair was admitted to the same ward with overlapping dates of 
admission; indirect ward contact if admitted to the same ward with no overlapping dates; direct 
hospital-wide contact if admitted to the same hospital in different wards with overlapping dates, 
and indirect hospital-wide contact if admitted to the same hospital in different wards with no 
overlapping dates. We identified episodes of hospital admission for each case in the 12-month 
period prior to their first MRSA-positive sample. Information on outpatient clinic appointments 
was not available. Community contact was classified if cases shared a postcode or had their 
MRSA-positive sample submitted by the same GP practice. Community contacts were further 
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categorized as household contact if people shared a residential address; LTCF contact if they 
lived in the same LTCF; or GP contact if they were registered with the same GP practice. 
Information on GP visits were not available other than that recorded for cases with MRSA swabs 
collected at GP practices. In a few instances, cases shared the same postcode but lived at a 
different residential address. In a minority of cases, patient addresses could not be retrieved from 
clinical records and were classified as ‘unresolved’. We studied cases positive for MRSA CC22 
to determine the frequency of different types of epidemiological contact among genetically 
unrelated cases, using a pairwise SNP distance greater than 50 SNPs. This analysis led us to 
consider epidemiological links as strong if they were ward contacts (other than A&E, GP 
contacts or shared postcodes, and weak if they were hospital-wide contacts and A&E (see 
Supplementary Methods for details). 
 
Identification of putative MRSA transmission  
Selecting a SNP cut-off to define MRSA transmission clusters was informed by two independent 
lines of evidence. First, we established the genetic diversity of the same MRSA clone in a single 
individual (pool of diversity) in 26 cases with more than one isolate (range 2 to 3, median 2) 
from independent samples cultured on the same day. The maximum genetic distance of MRSA 
in each case ranged from 0 to 41 SNPs (median 2, IQR 1 to 3), which is comparable to the 
maximum within-host diversity reported elsewhere (19–21). In parallel, we selected the single 
largest phylogenetic cluster containing isolates from cases with strong epidemiological links (13 
cases, a putative outbreak) and established that the pairwise genetic distance between cases 
ranged from 0 to 48 SNPs. We constructed CC-based phylogenetic trees and then sub-divided 
each tree into clusters based on a SNP distance of no more than 50, and looked for hospital and 
community contacts between cases residing in the same genetic cluster. Clusters were 
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categorized as containing community contacts alone; hospital contacts alone; community AND 
hospital contacts; or no known hospital/community contacts. For clusters with hospital and/or 
community contacts involving five or more cases, we incorporated individual patient movement 
data (for in-patients), sampling dates, MRSA screen results and bacterial phylogeny to identify 
the most plausible MRSA source. Supplementary Materials and Methods and figs. S2 and S3 
describe in more detail how genomic and epidemiological data were integrated to identify and 
classify transmission clusters. 
 
Supplementary Materials 
Materials and Methods 
Fig. S1. Number of isolates sequenced per patient 
Fig. S2. Flowchart summarizing data types and analyses 
Fig. S3. Integration of genomic and epidemiological data to identify transmission clusters 
Fig. S4. Six examples of transmission clusters in different settings 
Fig. S5. Number of heterozygous sites in the core genome per isolate 
Fig. S6. Within-host diversity over time and at a single time point 
Table S1. Proportion of isolates in different clonal complexes 
Table S2. Frequency of epidemiological contacts among genetically unrelated cases 
Table S3. Epidemiological classification of transmission clusters containing 5 or more cases 
Data file S1. SupplementaryData1.xlsx 
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Figures 
Fig. 1. Map showing the study catchment area in the East of England.   
The locations of hospitals (n=3), GP practices (n=75) and postcode districts are shown for the 
1,465 study cases. Postcode districts are color-coded to show the number of MRSA positive 
cases sampled in each district. A total of 5,012,137 residents lived in the highlighted districts 
(16,240 km2) according to the 2011 UK Census. 
 
Fig. 2. Pairwise comparison between MRSA relatedness and type of patient contact.  
For each case, the most closely related MRSA isolate from another case was identified and the 
epidemiological contact of each case-pair defined. The number of cases in each epidemiological 
category is shown as a function of the genetic distance. Panels A to D show the genetic distance 
distribution for cases with hospital contacts alone. Direct contact refers to a link in the same time 
and place (ward or hospital). Indirect contact refers to a link in the same place but different time. 
Panel E shows community contacts. Cases with neither hospital nor community contacts are 
shown in panel F. Only cases with MRSA isolates from clonal complexes found in at least one 
other patient in the population are shown (n=1,459). 
 
Fig. 3. Transmission clusters color coded on the CC22 phylogeny.  
Maximum likelihood tree generated from 34,600 SNP sites in the core genome is shown for 
1,667 CC22 isolates. Colors refer to type of epidemiological links in clusters of genetically 
related isolates (maximum 50 SNPs) from multiple cases. 
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Fig. 4. Exemplars of two patterns of nosocomial MRSA spread 
A. Ward-centric. Eight patients in this transmission cluster had ward contacts in ward B2 and 
B21, including admission overlaps. Of note, the putative epicentre of transmission was in wards 
B2 or B21 but the outbreak strain was isolated on later admissions in 6 of the 8 patients, 3 of 
which (1090, 727 and 762) were first detected at a different hospital (hospital A) from where 
they had putatively acquired this (hospital B).  
B. Patient-centric. Six patients had stayed in wards visited by patient 388 (i.e. A49, A80 and 
A59) prior to their MRSA isolation date. Negative MRSA screens prior to entry to these wards 
for some patients (1288, 1057, 1488, 1377 and 942) further supports hospital acquisition. Isolates 
from patient 388 were the most basal in the phylogenetic tree and their diversity enclosed that of 
the other patients, providing further indicators for this patient being the potential source for the 
transmission cluster. Colored blocks other than grey represent ward contacts, which are labelled 
by a letter to denote the hospital (A or B) and a number that denotes the anonymised ward.  
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Table 1. Epidemiological classification of transmission clusters.  
Columns are ordered based on decreasing proportion of isolates in each CC. Each cell shows the 
number of cases and (in brackets) the number of transmission clusters to which these cases were 
assigned. The number of transmission clusters in each category is the sum of those of its sub-
categories. The same applies to the number of cases except for column ‘CC22’ and ‘Overall’. A 
total of 7 cases had two different CC22 strains suggestive of mixed colonisation or strain 
replacement that linked them to two different transmission clusters. This explains why the total 
number of genetically clustered cases (n=578) is lower than the sum of cases in its sub-
categories. CCs with genetically unrelated isolates or isolated once from the study population are 
not shown. ‘Multiple hospitals’ refers to epidemiological contacts from more than one of three 
study hospitals. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Epidemiological classification Overall CC22 CC30 CC5 CC1 CC8 CC45 CC59 CC80 CC15 CC361 
Genetically unrelated cases 680 462 36 49 35 42 17 15 6 1 2 
Genetically clustered with other cases 785  578  46  30  45  9  34  26  9  9  3  
Genetically clustered & epidemiological contacts 598 (173) 449 (127) 36 (8) 20 (9) 33 (13) 4 (2) 24 (8) 21 (3) 2 (1) 8 (1) 3 (1) 
Only community contacts 72 (27) 50 (17) 3 (1) 3 (1) 6 (3) 4 (2) 4 (2) - 2 (1) - - 
Different postcode Shared GP practice 14 (3) 10 (1) - - 2 (1) - 2 (1) - - - - 
Same postcode Shared Household 25 (11) 16 (7) 3 (1) - - 4 (2) - - 2 (1) - - 
Same postcode Shared LTCF 22 (8) 20 (7) - - - - 2 (1) - - - - 
Same postcode Different addresses 2 (1) - - - 2 (1) - - - - - - 
Same postcode Unresolved 9 (4) 4 (2) - 3 (1) 2 (1) - - - - - - 
Only hospital contacts 371 (118) 296 (91) 10 (3) 15 (7) 20 (8) - 16 (5) 5 (2) - 8 (1) 3 (1) 
Ward contact 255 (64) 212 (52) 6 (1) 5 (2) 10 (4) - 9 (2) 3 (1) - 8 (1) 3 (1) 
Hospital A 125 (41) 101 (35) 6 (1) - 6 (2) - 9 (2) - - - 3 (1) 
Hospital B 48 (14) 32 (10) - 3 (1) 2 (1) - - 3 (1) - 8 (1) - 
Hospital C  8 (4) 4 (2) - 2 (1) 2 (1) - - - - - - 
Multiple hospitals 75 (5) 75 (5) - - - - - - - - - 
Hospital-wide contact 118 (54) 85 (39) 4 (2) 10 (5) 10 (4) - 7 (3) 2 (1) - - - 
Hospital A 97 (45) 70 (33) 2 (1) 8 (4) 8 (3) - 7 (3) 2 (1) - - - 
Hospital B 6 (3) 2 (1) 2 (1) - 2 (1) - - - - - - 
Hospital C  8 (4) 6 (3) - 2 (1) - - - - - - - 
Multiple hospitals 8 (2) 8 (2) - - - - -  - - - 
Both hospital and community contacts 156 (28) 104 (19) 23 (4) 2 (1) 7 (2) - 4 (1) 16 (1) - - - 
Different postcode Shared GP practice 13 (2) 13 (2) - - - - - - - -  
Same postcode Shared Household 37 (9) 17 (3) 11 (3) 2 (1) 3 (1) - 4 (1) - - - - 
Same postcode Shared LTCF 56 (9) 36 (7) - - 4 (1) - - 16 (1) - - - 
Same postcode Different addresses 17 (3) 5 (2) 12 (1) - - - - - - - - 
Same postcode Unresolved 33 (5) 33 (5) - - - - - - - - - 
Neither hospital nor community contacts 193 134 10 10 12 5 10 5 7 - - 
Total number of cases 1465 1040 82 79 80 51 51 41 15 9 5 
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Materials and Methods 
Case data and sequencing strategy 
Patient medical records were reviewed to collect routine epidemiological and microbiological 
data. This included date and ward of hospital admission and discharge. Information on ward 
transfers during the same admission were also collected from the hospital bed tracking 
system, what provided information on the location of methicillin-resistant Staphylococcus 
aureus (MRSA) cases in relation to other MRSA carriers and non-MRSA carriers. Full 
postcodes were obtained from electronic healthcare records. A full postcode in the United 
Kingdom (UK) designates a restricted area with a small number of addresses. 
 
Selection of isolates for sequencing was performed as follows. The first MRSA isolate 
cultured from each case was sequenced. Some cases had more than one MRSA-positive 
culture during the same admission. If screening swabs and clinical samples were positive, an 
isolate from each of the two categories were sequenced. If MRSA was available from more 
than one clinical sample, the isolate from a sterile site sample took preference over isolates 
from colonized sites. All blood culture isolates were sequenced. Each admission was treated 
as an independent event and the rule base above reapplied.  
 
Microbiology and DNA sequencing 
MRSA was isolated by plating screening swabs onto Brilliance MRSA chromogenic medium 
(Oxoid, Basingstoke, UK) and from all other samples by plating onto Columbia Blood Agar 
(Oxoid, Basingstoke, UK). S. aureus was identified using a commercial latex agglutination 
kit (Pastorex Staph Plus, Bio Rad Laboratories, Hemel Hempstead, UK). One colony was 
randomly selected for downstream processing. Positive cases and their isolates were assigned 
a unique anonymous identification code. Bacterial DNA was extracted using the QIAxtractor 
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kit (QIAgen, Hilden, Germany), and anonymised DNA samples were transferred to the 
Wellcome Trust Sanger Institute for sequencing.  
 
Genomic analyses 
Genomes for the 2,282 MRSA isolates were de novo assembled using an iterative process 
involving Velvet (1) version 1.2.09, SSPACE (2) v2.0, GapFiller (3) v1.11, BWA (4) v0.7.12 
and Bowtie (5) v1.1.0 as explained elsewhere (11).  
 
Thirty-eight isolate genomes were excluded including 6 isolates that were found to be 
Staphylococcus haemolyticus (n=5) or Staphylococcus sciuri (n=1); 4 isolates were S. aureus 
but were not MRSA (i.e. mecA and mecC negative); 8 isolates were duplicates; 6 isolates had 
missing epidemiological or other information; 2 genomes had a low number of reads 
(<1,000,000); 8 MRSA genomes had a high number of heterozygous sites (>10,000 see fig. 
S5) and very fragmented assemblies, suggestive of multiple MRSA clones being sequenced; 
and 4 genomes had an abnormal position in the phylogeny (suggestive of contamination).  
 
Sequence types (STs) were derived from de novo assemblies by extracting all seven S. aureus 
MLST loci and comparing them to the PubMLST database (www.PubMLST.org). Clonal 
complexes (CCs) were derived from the allelic profile, allowing up to two allele mismatches 
from the reference ST. All isolates belonging to the same clonal complex (CC) were mapped 
using SMALT v0.7.4 to a closely related reference genome, as follows: ST22 strain HO 5096 
0412 (accession number HE681097), ST30 strain MRSA252 (BX571856), ST5 strain N315 
(BA000018), ST1 strain MW2 (BA000033), ST8 strain USA300 FPR3757 (CP000255), 
ST45 strain CA-347 (CP006044.1), ST59 strain M013 (CP003166.1) and ST80 strain 11819-
97 (CP003194.1). In addition, all isolates were mapped to the ST22 reference genome. 
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Single-nucleotide polymorphisms (SNPs) were called from BAM files using SAMTOOLS 
v0.1.19 using default parameters. Heterozygous sites were called if the non-reference allele 
was represented by 20 to 80% of the reads. Supplementary Data 1 provides a full list of 
isolates, accession numbers, STs and quality control (QC) metrics. 
 
Whole genome alignments were created for CC22, CC30, CC5, CC1, CC8, CC45, CC59 and 
CC80 using SNPs derived from mapping of isolates to their corresponding reference genome. 
Whole genome alignments for CCs containing fewer than 10 cases (CC15, CC130, CC361, 
CC72, CC12 and CC88) were created with SNPs derived from mapping to the ST22 
EMRSA15 strain reference genome, since a genetically close reference genome was not 
available. Chromosomal regions containing mobile genetic elements were removed from the 
alignments and maximum likelihood trees created using RAxML v7.8.6 for each of the 
fourteen CCs. Pairwise genetic distances between isolates of the same CC were calculated 
based on the number SNPs in the core genome. These analyses were not conducted for 
STs/CCs which only occurred once (ST97, ST152, CC398, ST425, ST779 and ST1943). 
 
Within-host genetic diversity 
Within-host diversity of MRSA was determined for 346 cases who had more than one CC22 
isolate sequenced (n=970 isolates). The pairwise SNP distance in the core genome was 
determined for each pair of isolates from the same case. Figure S6A shows SNP distances 
binned by time between isolate collection times. Isolates collected within one month had a 
median genetic distance of 2 SNPs and isolates collected within 9 to 12 months apart had a 
median of 6 SNPs. We detected variability around these medians and hypothesized that a pre-
existing pool of diversity within individuals could be responsible for this. We therefore 
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evaluated cases having multiple isolates sequenced on the same day (n=26) and calculated the 
maximum within-host diversity (fig. S6B). The pool of diversity ranged from 0 to 41 SNPs. 
 
Identification and classification of transmission clusters 
Phylogenetic trees for each CC were partitioned into clusters using a “depth-first-search” 
algorithm (6). We used a maximum genetic distance of 50 SNPs at the core genome as a 
threshold to define clusters based on two criteria: (a) it is greater than the maximum within-
host SNP distance found in this study (fig. S6) (i.e. 41 SNPs), which in turn is comparable to 
that already reported (7–9), and (b) it is greater than the maximum SNP distance observed 
among isolates of different cases in the largest phylogenetic clade associated with strong 
epidemiological links (fig. S2A). We then focused on clusters  harboring multiple cases and 
studied epidemiological links – ward, hospital and community contacts – among them. In the 
context of this study, a transmission cluster was defined as two or more cases whose MRSA 
isolates were genetically related - forming a monophyletic clade in the tree of a maximum of 
50 SNPs – and with epidemiological links supporting transmission. See fig. S2 and S3 for a 
schematic representation of how genomic and epidemiological data were integrated to 
identify transmission clusters.  
 
Inference of transmission routes 
For transmission clusters involving five or more people, case location was plotted over the 
time of the study using R. Sample collection times, MRSA screen results and the phylogeny 
were taken into account to visually identify the most plausible ward/source where MRSA was 
putatively acquired.  
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Supplementary Figures 
Fig. S1. Number of isolates sequenced per patient 
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Fig. S2.  Flowchart summarizing data types and analyses 
 
QC1 refers to samples discarded due to low number of reads (n=2) and those that were 
duplicates or had missing information (n=14), QC2 to samples that were not MRSA (n=4) or 
S. aureus (n=6) and QC3 to samples filtered out due to high number of heterozygous sites 
(n=8, fig. S5) or abnormal position in the phylogeny (n=4). Abbreviations: QC, quality 
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control; MGE, mobile genetic elements; MLST, multi-locus sequence type; TC, transmission 
cluster. 
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Fig. S3. Integration of genomic and epidemiological data to identify transmission clusters 
 
A hypothetical example is shown to illustrate how bacterial phylogeny and patient 
epidemiological data were used to define and classify transmission clusters. First, 
phylogenetic trees were partitioned into clusters based on a maximum genetic distance of 50 
SNPs in the core genome. Numbers on branches show SNP distances. The diagram shows 
two genetic clusters that contain MRSA isolates from two and four cases respectively. Pt1 
and Pt4 isolates were not clustered and thus classified as ‘genetically unrelated’. 
Epidemiological links between cases within the same cluster were then defined. In cluster A, 
Pt2 and Pt3 had no previous hospital contact but shared the same residential postcode and 
was classified as a ‘community’ cluster. In cluster B, three out of four cases had stayed in the 
same hospital ward and did not share the same postcode, forming a ‘hospital’ cluster. In some 
cases (e.g. Pt7), hospital acquisition was supported by a previous negative MRSA screen. Pt5 
had no epidemiological links despite being clustered and was therefore not included in the 
transmission cluster. 
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Fig. S4. Six examples of transmission clusters in different settings 
LEGEND KEY: Colored blocks other than grey represent ward contacts, which are labelled 
by a letter to denote hospital or GP (A, B or GP) and a random number that denotes the 
anonymized ward or GP. 
 
A. Transmission cluster centered around a GP practice (CC22) 
 
The median bacterial pairwise genetic distance between cases was 16 SNPs (range 0 – 48). 
10/13 cases had samples taken at the same GP practice (GP52). 9/13 cases had no recorded 
hospital admission in the previous year, ruling out recent nosocomial acquisition. All cases 
had different postcodes except for 621 and 1395. Cases 621, 737 and 1033 all had MRSA 
samples taken at hospital A but were also registered to GP52. 
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B. Community transmission cluster at a LTCF (CC22) 
 
The median bacterial pairwise genetic distance between cases was 27 SNPs (range 5 – 46). 
Six of 8 cases resided in the same LTCF (excluding 909 and 1345). In three cases (patient 81, 
165 and 524), the MRSA-positive sample was submitted by the same GP practice (GP21), 
while the remainder were taken at hospital A. No epidemiological links were identified for 
cases 909 and 1345.  
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C. Community transmission cluster involving households and a GP practice (CC22) 
 
The median bacterial pairwise genetic distance between cases was 47 SNPs (range 5 – 48). 
4/5 cases had community epidemiological links. Cases 658 and 1386 shared a residential 
address, and cases 585 and 601 shared a residential address. Cases 658, 1386, 585 and 601 
were all registered with the same GP (GP23). Case 912 has no identifiable epidemiological 
link to the other cases.  
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D. Transmission cluster with both community and hospital epidemiological links (CC30) 
 
The median bacterial pairwise genetic distance between cases was 2 SNPs (range 0 – 5). 5/7 
cases had ward contacts on ward B2 and B22, including admission overlaps in ward B22. 
Cases 815 and 725 shared a residential address. The transmitted MRSA strain was isolated in 
all cases after case 725 was admitted into hospital, suggesting that this case may have 
introduced MRSA into this setting. Case 815 had no recorded hospital admission in the 
previous year, ruling out recent nosocomial acquisition. 
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E. Transmission cluster with both community and hospital epidemiological links (CC22) 
 
The median bacterial pairwise genetic distance between cases was 3 SNPs (range 0 – 8). 
Patient 345 appears to be the source in the transmission cluster as their isolates predated 
others, occupied the most basal position in the phylogenetic tree, and enclosed those from the 
other seven cases. Patient 345 appears to have acquired MRSA at hospital B as two negative 
screens preceded the first positive sample. All other cases except 884 are epidemiologically 
linked to patient 345 including contact on ward B18 (case 696), B2/B22 (cases 918, 949, 
891), B11 (case 44) and GP23 (case 1444).  Case 345 was colonized by the same MRSA 
strain for 9 months.  
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F.  Transmission cluster with both community and hospital epidemiological links. Household 
transmission followed by onward hospital transmission. (CC30) 
 
The median bacterial pairwise genetic distance between cases was 3 SNPs (range 0 – 12). 
Cases 1091, 1264, 715 had no hospital contact in the past year but shared a residential 
address. Cases 1119 and 1097 were admitted to ward A77 after patient 715 had been 
discharged (indirect ward contact). MRSA isolates from cases 1119, 1097 and 715 were 0 
SNPs apart, supporting recent transmission. Case 399 had no identifiable epidemiological 
link to the other cases.  
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Figure S5. Number of heterozygous sites in the core genome per isolate 
 
A total of 11 genomes (3 Staphylococcus haemolyticus and 8 Staphylococcus aureus) with 
>10,000 heterozygous sites were assumed to be contaminated and were discarded from 
further analyses. 
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Figure S6.  Within-host diversity over time and at a single time point 
 
A. Genetic distance between pairs of isolates taken from the same case. A total of 346 cases 
with 970 CC22 isolates were used in the analysis. On the x-axis, the time gap in days 
between isolate collection times is shown. On the y-axis, SNP distances between pairs of 
isolates from the same patient. The width of the box plots reflects the number of data points.  
B. Maximum genetic distance observed among MRSA isolates taken from the same patient 
on the same day. A total of 26 cases with 55 CC22 isolates were used in the analysis (2 to 3 
isolates per case). The color of each point indicates the specimen type from which isolates 
being compared were cultured (green for screen vs. screen, orange for clinical vs. clinical, 
and purple for screen vs. clinical sample). On the x-axis, case identifiers are shown. 
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Supplementary Tables 
Table S1.  Proportion of isolates in different clonal complexes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*A total of 9 cases had isolates from two different CCs. In one case three different CCs were 
sequenced.  
  
CC Number of Isolates 
Percentage of 
Isolates (%) 
Number of 
individuals 
22 1667 73.05 1040 
30 129 5.65 82 
5 108 4.73 79 
1 105 4.60 80 
8 87 3.81 51 
45 70 3.07 51 
59 50 2.19 41 
80 19 0.83 15 
361 11 0.48 5 
130 10 0.44 9 
15 10 0.44 9 
72 5 0.22 3 
97 2 0.09 1 
12 2 0.09 2 
88 2 0.09 2 
152 1 0.04 1 
1943 1 0.04 1 
398 1 0.04 1 
425 1 0.04 1 
779 1 0.04 1 
Total 2282 100 1465* 
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Table S2. Frequency of epidemiological contacts among genetically unrelated cases 
 
 
A total of 1,040 cases with CC22 isolates were available, resulting in 540,280 case-pair 
comparisons. Of these, 534,417 case pairs had genetically unrelated MRSA isolates, i.e. more 
than 50 SNPs apart. The table shows the frequency of three different types of epidemiological 
contacts among these 534,417 comparisons. 
  
Hospital-wide contacts  
Both cases not admitted to the same hospital 313,269 (58.61%) 
Both cases admitted to Hospital A 195,222 (36.2%) 
Both cases admitted to Hospital B 14,295 (2.67%) 
Both cases admitted to Hospital C 11,631 (2.18%) 
  
Ward or GP contacts  
Both cases did not visit the same ward or GP practice 453,753 (84.90%) 
Both cases seen as a patient in A&E 37,340 (6.99%) 
Both cases admitted to the same ward or GP 2,933 or less (0.55% or less) 
  
Postcode contacts  
Postcodes not available for comparison 64,898 (12.14%) 
Both cases had different postcodes  469,309 (87.82%) 
Both cases had the same postcode 210 (0.04%) 
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Table S3. Epidemiological classification of transmission clusters containing 5 or more cases 
 
CC TC Cases Classification Transmission Pattern Figure 
CC22 285-B 44 Hospital Hospital-centric (hospital A) Not Shown 
CC22 285-A 21 Hospital Ward-centric (hospital B) Figure 2A 
CC22 194-A 10 Hospital Hospital-centric (hospital A) Not Shown 
CC22 248-A 8 Hospital Hospital-centric (hospital B) Not Shown 
CC15 1-A 8 Hospital Ward-centric (hospital B) Not Shown 
CC30 14-A 6 Hospital Ward-centric (hospital A) Not Shown 
CC22 53-A 6 Hospital Hospital-centric (hospital A) Not Shown 
CC45 6-A 6 Hospital Hospital-centric (hospital A) Not Shown 
CC22 94-A 5 Hospital Hospital-centric (hospital A) Not Shown 
CC22 144-A 13 Community Centred at GP practice Fig S2 A 
CC22 242-A 6 Community Centred at LTCF Fig S2 B 
CC59 4-A 16 Hospital/Community Centred at two LTCF + hospital wide contacts 
in hospital A 
Not shown 
CC30 4-A 12 Hospital/Community Centred at household + ward contacts in 
hospital B 
Fig S2 D 
CC22 241-A 11 Hospital/Community Centred at LTCF + ward contacts in hospital A Not Shown 
CC22 227-A 11 Hospital/Community Unresolved community contact + ward contacts 
in hospital A 
Not Shown 
CC22 113-A 8 Hospital/Community Centred at two households + hospital-wide 
contacts in hospital A 
Not Shown 
CC22 237-A 7 Hospital/Community Centred at GP + patient centric in hospital B Fig S2 E 
CC22 106-A 7 Hospital/Community Unresolved community contact + ward contacts, 
patient centric in hospital A 
Figure 2B 
CC22 74-A 7 Hospital/Community Unresolved community contact + ward contacts 
in hospital B 
Not Shown 
CC22 138-A 6 Hospital/Community Centred at GP practice + ward contacts in 
hospital A 
Not Shown 
CC22 79-A 5 Hospital/Community Unresolved community contact + ward contacts 
in hospital B 
Not Shown 
CC22 105-A 5 Hospital/Community Centred at household + ward contacts in 
hospital A 
Not Shown 
CC22 48-A 5 Hospital/Community Centred at LTCF + ward contacts in hospital A Not Shown 
CC22 125-A 5 Hospital/Community Centred at LTCF + hospital-wide contacts in 
hospital A 
Not Shown 
CC30 1-A 5 Hospital/Community Centred at household + patient centric in 
hospital A 
Fig S2 F 
CC22 259-A 5 Hospital/Community Centred at LTCF + ward contacts in hospital A Not Shown 
 
